Literature DB >> 19341729

Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone.

Emilia Barcia1, Rocío Herrero-Vanrell, Ana Díez, Consuelo Alvarez-Santiago, Isabel López, Margarita Calonge.   

Abstract

We tested the short- and long-term ability of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone to reduce ocular inflammation in rabbits elicited by intravitreal lipopolysaccharide (LPS) injection. PLGA microspheres loaded with dexamethasone were prepared by the solvent evaporation technique from an oil/water emulsion and sterilized by gamma irradiation (25 kGy). The microsphere fraction selected was 2:10 (dexamethasone:PLGA) and contained 141 +/- 0.38 microg dexamethasone/mg PLGA. Microsphere diameters were 20-53 microm, and the mean encapsulation efficiency was 92.97 +/- 0.75%. Seven days prior to the induction of panuveitis, 10 mg of dexamethasone-free or dexamethasone-loaded microspheres were injected into the vitreous. Control animals received no injection. Panuveitis was induced in male New Zealand rabbits (2.5-3.0 kg) by intravitreal injection of Escherichia coli LPS. Clinical evaluation, electroretinography and histopathologic studies were performed in short-term studies of 15 days and in long-term studies of 33 days. Efficacy in reducing inflammation was also studied in vitrectomized eyes. In short-term studies eyes injected with dexamethasone-loaded microspheres had less inflammation than control eyes and eyes injected with blank microspheres. Inflammation reverted in all groups by 15 days after LPS injection. A second LPS dose given on Day 30 provoked a high peak of inflammation in control eyes and in those injected with blank microspheres. In contrast, only slight inflammation occurred in eyes injected with dexamethasone-loaded microspheres. Histopathology and electroretinography supported these results. Dexamethasone-loaded microspheres effectively reduced intraocular inflammation caused by LPS in both short- and long-term studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19341729     DOI: 10.1016/j.exer.2009.03.012

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  14 in total

Review 1.  Emerging role of antioxidants in the protection of uveitis complications.

Authors:  U C S Yadav; N M Kalariya; K V Ramana
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  In vitro, in vivo, and in silico evaluation of the bioresponsive behavior of an intelligent intraocular implant.

Authors:  Lisa C du Toit; Trevor Carmichael; Thirumala Govender; Pradeep Kumar; Yahya E Choonara; Viness Pillay
Journal:  Pharm Res       Date:  2013-09-04       Impact factor: 4.200

Review 3.  Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema.

Authors:  Marco Dutra Medeiros; Micol Alkabes; Paolo Nucci
Journal:  Eur Endocrinol       Date:  2014-08-28

Review 4.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

5.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

6.  Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis.

Authors:  Wenchang Li; Bing He; Wenbing Dai; Qiang Zhang; Yuling Liu
Journal:  Int Ophthalmol       Date:  2013-07-19       Impact factor: 2.031

7.  Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications.

Authors:  Jiaxin Liu; Xueyan Zhang; Ge Li; Fei Xu; Shuang Li; Lesheng Teng; Youxin Li; Fengying Sun
Journal:  Int J Nanomedicine       Date:  2019-11-08

8.  Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema.

Authors:  Rocío Herrero-Vanrell; Jose Augusto Cardillo; Baruch D Kuppermann
Journal:  Clin Ophthalmol       Date:  2011-02-01

9.  Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.

Authors:  Jorge L Jacot; David Sherris
Journal:  J Ophthalmol       Date:  2011-10-30       Impact factor: 1.909

10.  A biodegradable, sustained-released, prednisolone acetate microfilm drug delivery system effectively prolongs corneal allograft survival in the rat keratoplasty model.

Authors:  Yu-Chi Liu; Yan Peng; Nyein Chan Lwin; Subbu S Venkatraman; Tina T Wong; Jodhbir S Mehta
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.